Taub Rebecca, a director at Madrigal Pharmaceuticals ($MDGL), sold common shares on the open market 64 times over the last year, totaling $48.8 million. Her most recent sale occurred on March 6, 2026. These sales rank her 325th among 11,678 insiders by total value sold, well above the average of $8.6 million across 6.4 transactions per insider. She made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 6, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 491 | $431.94 | 1,107,753.0000 | 22,939,969 | 0.04% | 0.00% |
| Jan. 26, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 647 | $492.42 | 1,108,244.0000 | 22,711,420 | 0.06% | 0.00% |
| Jan. 20, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 2238 | $490.77 | 1,108,891.0000 | 22,711,420 | 0.20% | 0.01% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | M | Common Stock | 240 | $15.80 | 1,111,369.0000 | 22,711,420 | 0.02% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | M | Common Stock | 18410 | $15.80 | 1,129,539.0000 | 22,711,420 | 1.66% | 0.08% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 200 | $551.24 | 1,111,129.0000 | 22,711,420 | 0.02% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 40 | $545.79 | 1,111,329.0000 | 22,711,420 | 0.00% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 732 | $522.98 | 1,119,270.0000 | 22,711,420 | 0.07% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 588 | $521.95 | 1,120,002.0000 | 22,711,420 | 0.05% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 440 | $521.11 | 1,120,590.0000 | 22,711,420 | 0.04% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 539 | $519.89 | 1,121,030.0000 | 22,711,420 | 0.05% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 970 | $518.67 | 1,121,569.0000 | 22,711,420 | 0.09% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 2044 | $517.84 | 1,122,539.0000 | 22,711,420 | 0.18% | 0.01% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 521 | $516.81 | 1,124,583.0000 | 22,711,420 | 0.05% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 1578 | $515.82 | 1,125,104.0000 | 22,711,420 | 0.14% | 0.01% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 937 | $514.63 | 1,126,682.0000 | 22,711,420 | 0.08% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 960 | $513.12 | 1,127,619.0000 | 22,711,420 | 0.09% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 960 | $512.02 | 1,128,579.0000 | 22,711,420 | 0.08% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | M | Stock Option (Right to Buy) | 240 | $0.00 | 0.0000 | 22,711,420 | 100.00% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | M | Stock Option (Right to Buy) | 18410 | $0.00 | 240.0000 | 22,711,420 | 98.71% | 0.08% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 400 | $542.72 | 1,111,129.0000 | 22,711,420 | 0.04% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 40 | $540.26 | 1,111,529.0000 | 22,711,420 | 0.00% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 400 | $539.26 | 1,111,569.0000 | 22,711,420 | 0.04% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 40 | $537.84 | 1,111,969.0000 | 22,711,420 | 0.00% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 385 | $536.88 | 1,112,009.0000 | 22,711,420 | 0.03% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 299 | $535.80 | 1,112,394.0000 | 22,711,420 | 0.03% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 89 | $534.93 | 1,112,693.0000 | 22,711,420 | 0.01% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 271 | $534.18 | 1,112,782.0000 | 22,711,420 | 0.02% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 40 | $532.50 | 1,113,053.0000 | 22,711,420 | 0.00% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 30 | $531.05 | 1,113,093.0000 | 22,711,420 | 0.00% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 256 | $530.45 | 1,113,123.0000 | 22,711,420 | 0.02% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 554 | $529.28 | 1,113,379.0000 | 22,711,420 | 0.05% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 465 | $528.16 | 1,113,933.0000 | 22,711,420 | 0.04% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 1135 | $526.95 | 1,114,398.0000 | 22,711,420 | 0.10% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 913 | $526.05 | 1,115,533.0000 | 22,711,420 | 0.08% | 0.00% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 1489 | $525.12 | 1,116,446.0000 | 22,711,420 | 0.13% | 0.01% |
| Jan. 9, 2026 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 1335 | $524.06 | 1,117,935.0000 | 22,711,420 | 0.12% | 0.01% |
| Dec. 10, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 1027 | $554.84 | 1,116,784.0000 | 22,711,420 | 0.09% | 0.00% |
| Dec. 10, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 3087 | $553.88 | 1,117,811.0000 | 22,711,420 | 0.28% | 0.01% |
| Dec. 10, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 3857 | $552.81 | 1,120,898.0000 | 22,711,420 | 0.34% | 0.02% |
| Dec. 10, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 4410 | $551.85 | 1,124,755.0000 | 22,711,420 | 0.39% | 0.02% |
| Dec. 10, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 4723 | $550.99 | 1,129,165.0000 | 22,711,420 | 0.42% | 0.02% |
| Dec. 10, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 486 | $550.07 | 1,133,888.0000 | 22,711,420 | 0.04% | 0.00% |
| Dec. 10, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 369 | $548.56 | 1,134,374.0000 | 22,711,420 | 0.03% | 0.00% |
| Dec. 10, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 491 | $547.76 | 1,134,743.0000 | 22,711,420 | 0.04% | 0.00% |
| Dec. 10, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | M | Common Stock | 18650 | $15.80 | 1,135,234.0000 | 22,711,420 | 1.67% | 0.08% |
| Dec. 10, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 200 | $555.39 | 1,116,584.0000 | 22,711,420 | 0.02% | 0.00% |
| Dec. 10, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | G | Common Stock | 5455 | $0.00 | 1,111,129.0000 | 22,711,420 | 0.49% | 0.02% |
| Dec. 10, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | M | Stock Option (Right to Buy) | 18650 | $0.00 | 18,650.0000 | 22,711,420 | 50.00% | 0.08% |
| Aug. 11, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | M | Common Stock | 3200 | $9.45 | 1,119,784.0000 | 22,080,246 | 0.29% | 0.01% |
| Aug. 11, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 2980 | $350.18 | 1,116,804.0000 | 22,080,246 | 0.27% | 0.01% |
| Aug. 11, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 220 | $351.02 | 1,116,584.0000 | 22,080,246 | 0.02% | 0.00% |
| Aug. 12, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | M | Common Stock | 43263 | $9.45 | 1,159,847.0000 | 22,080,246 | 3.87% | 0.20% |
| Aug. 12, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 3580 | $350.87 | 1,156,267.0000 | 22,080,246 | 0.31% | 0.02% |
| Aug. 12, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 2870 | $351.60 | 1,153,397.0000 | 22,080,246 | 0.25% | 0.01% |
| Aug. 12, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 1175 | $352.45 | 1,152,222.0000 | 22,080,246 | 0.10% | 0.01% |
| Aug. 12, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 4587 | $354.04 | 1,147,635.0000 | 22,080,246 | 0.40% | 0.02% |
| Aug. 12, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 6479 | $354.97 | 1,141,156.0000 | 22,080,246 | 0.56% | 0.03% |
| Aug. 12, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 5752 | $355.95 | 1,135,404.0000 | 22,080,246 | 0.50% | 0.03% |
| Aug. 12, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 4864 | $356.88 | 1,130,540.0000 | 22,080,246 | 0.43% | 0.02% |
| Aug. 12, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 6715 | $357.85 | 1,123,825.0000 | 22,080,246 | 0.59% | 0.03% |
| Aug. 12, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 6541 | $358.81 | 1,117,284.0000 | 22,080,246 | 0.58% | 0.03% |
| Aug. 12, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 700 | $359.71 | 1,116,584.0000 | 22,080,246 | 0.06% | 0.00% |
| Aug. 11, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | M | Stock Option (Right to Buy) | 3200 | $0.00 | 43,263.0000 | 22,080,246 | 6.89% | 0.01% |
| Aug. 12, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | M | Stock Option (Right to Buy) | 43263 | $0.00 | 0.0000 | 22,080,246 | 100.00% | 0.20% |
| July 18, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 1000 | $350.01 | 1,116,584.0000 | 22,080,246 | 0.09% | 0.00% |
| July 18, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | M | Common Stock | 1000 | $9.45 | 1,117,584.0000 | 22,080,246 | 0.09% | 0.00% |
| July 18, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | M | Stock Option (Right to Buy) | 1000 | $0.00 | 46,463.0000 | 22,080,246 | 2.11% | 0.00% |
| July 16, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | M | Common Stock | 26444 | $9.45 | 1,143,028.0000 | 22,080,246 | 2.37% | 0.12% |
| July 17, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | M | Stock Option (Right to Buy) | 2657 | $0.00 | 47,463.0000 | 22,080,246 | 5.30% | 0.01% |
| July 16, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | M | Stock Option (Right to Buy) | 26444 | $0.00 | 50,120.0000 | 22,080,246 | 34.54% | 0.12% |
| July 17, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 600 | $351.50 | 1,116,584.0000 | 22,080,246 | 0.05% | 0.00% |
| July 17, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 2057 | $350.09 | 1,117,184.0000 | 22,080,246 | 0.18% | 0.01% |
| July 17, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | M | Common Stock | 2657 | $9.45 | 1,119,241.0000 | 22,080,246 | 0.24% | 0.01% |
| July 16, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 1380 | $356.52 | 1,116,584.0000 | 22,080,246 | 0.12% | 0.01% |
| July 16, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 6441 | $355.61 | 1,117,964.0000 | 22,080,246 | 0.57% | 0.03% |
| July 16, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 5800 | $354.61 | 1,124,405.0000 | 22,080,246 | 0.51% | 0.03% |
| July 16, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 2569 | $353.82 | 1,130,205.0000 | 22,080,246 | 0.23% | 0.01% |
| July 16, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 2357 | $352.64 | 1,132,774.0000 | 22,080,246 | 0.21% | 0.01% |
| July 16, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 1897 | $351.37 | 1,135,131.0000 | 22,080,246 | 0.17% | 0.01% |
| July 16, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Director | S | Common Stock | 6000 | $350.19 | 1,137,028.0000 | 22,080,246 | 0.52% | 0.03% |
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | A | Common Stock | 4382 | $0.00 | 1,116,584.0000 | 22,080,246 | 0.39% | 0.02% |
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | A | Stock Option (Right to Buy) | 7381 | $0.00 | 7,381.0000 | 22,080,246 | 9999.99% | 0.03% |
| Jan. 24, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 648 | $335.24 | 1,112,202.0000 | 0 | 0.06% | 0.00% |
| Jan. 17, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 1689 | $273.41 | 1,112,850.0000 | 0 | 0.15% | 0.00% |
| April 8, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | M | Common Stock | 2676 | $9.45 | 1,117,215.0000 | 0 | 0.24% | 0.00% |
| April 8, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 407 | $247.76 | 1,114,739.0000 | 0 | 0.04% | 0.00% |
| April 8, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 200 | $248.58 | 1,114,539.0000 | 0 | 0.02% | 0.00% |
| April 8, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 600 | $246.98 | 1,115,146.0000 | 0 | 0.05% | 0.00% |
| April 8, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | M | Stock Option (Right to Buy) | 2676 | $0.00 | 76,564.0000 | 0 | 3.38% | 0.00% |
| April 8, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 300 | $245.69 | 1,115,746.0000 | 0 | 0.03% | 0.00% |
| April 8, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 945 | $244.79 | 1,116,046.0000 | 0 | 0.08% | 0.00% |
| April 8, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 224 | $243.25 | 1,116,991.0000 | 0 | 0.02% | 0.00% |
| April 3, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | M | Common Stock | 27845 | $9.45 | 1,142,384.0000 | 0 | 2.50% | 0.00% |
| April 3, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | M | Stock Option (Right to Buy) | 27845 | $0.00 | 125,283.0000 | 0 | 18.18% | 0.00% |
| April 4, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | M | Stock Option (Right to Buy) | 18537 | $0.00 | 106,746.0000 | 0 | 14.80% | 0.00% |
| April 5, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | M | Stock Option (Right to Buy) | 27506 | $0.00 | 79,240.0000 | 0 | 25.77% | 0.00% |
| April 5, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 2079 | $244.45 | 1,119,817.0000 | 0 | 0.19% | 0.00% |
| April 5, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 8989 | $243.33 | 1,121,896.0000 | 0 | 0.79% | 0.00% |
| April 5, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 8817 | $242.61 | 1,130,885.0000 | 0 | 0.77% | 0.00% |
| April 5, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 700 | $241.14 | 1,139,702.0000 | 0 | 0.06% | 0.00% |
| April 5, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 1643 | $240.11 | 1,140,402.0000 | 0 | 0.14% | 0.00% |
| April 5, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | M | Common Stock | 27506 | $9.45 | 1,142,045.0000 | 0 | 2.47% | 0.00% |
| April 4, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 100 | $248.23 | 1,114,539.0000 | 0 | 0.01% | 0.00% |
| April 4, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 711 | $247.23 | 1,114,639.0000 | 0 | 0.06% | 0.00% |
| April 4, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 1653 | $246.01 | 1,115,350.0000 | 0 | 0.15% | 0.00% |
| April 4, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 2734 | $245.06 | 1,117,003.0000 | 0 | 0.24% | 0.00% |
| April 4, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 435 | $244.01 | 1,119,737.0000 | 0 | 0.04% | 0.00% |
| April 4, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 3085 | $242.71 | 1,120,172.0000 | 0 | 0.27% | 0.00% |
| April 4, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 5619 | $241.85 | 1,123,257.0000 | 0 | 0.50% | 0.00% |
| April 4, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 4200 | $240.88 | 1,128,876.0000 | 0 | 0.37% | 0.00% |
| April 4, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | M | Common Stock | 18537 | $9.45 | 1,133,076.0000 | 0 | 1.66% | 0.00% |
| April 3, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 2089 | $246.32 | 1,114,539.0000 | 0 | 0.19% | 0.00% |
| April 3, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 18917 | $245.34 | 1,116,628.0000 | 0 | 1.67% | 0.00% |
| April 3, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 4070 | $244.68 | 1,135,545.0000 | 0 | 0.36% | 0.00% |
| April 3, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 2634 | $243.68 | 1,139,615.0000 | 0 | 0.23% | 0.00% |
| April 3, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 135 | $242.00 | 1,142,249.0000 | 0 | 0.01% | 0.00% |
| April 5, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | S | Common Stock | 5278 | $245.53 | 1,114,539.0000 | 0 | 0.47% | 0.00% |
| Jan. 23, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | A | Market Stock Unit | 5786 | $0.00 | 5,786.0000 | 0 | 9999.99% | 0.00% |
| Jan. 23, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | A | Stock Option (Right to Buy) | 8718 | $0.00 | 8,718.0000 | 0 | 9999.99% | 0.00% |
| Jan. 23, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | A | Common Stock | 5786 | $0.00 | 1,114,539.0000 | 0 | 0.52% | 0.00% |
| Jan. 16, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Taub Rebecca | Pres., R&D, and CMO | F | Common Stock | 1546 | $243.92 | 1,108,753.0000 | 0 | 0.14% | 0.00% |